HRTX logo

Heron Therapeutics (HRTX)

Profile

Full Name

Heron Therapeutics, Inc.

Ticker Symbol

HRTX

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

August 26, 1987

Indexes

Not included

Website

http://www.herontx.com

Employees

122

Key Details

Price

$1.91(+4.95%)

Market cap

$290.95M(Small cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$144.28M(+13.57% YoY)

Annual EPS

-$0.09(+88.75% YoY)

PE ratio

-

Next earnings date

May 7, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$1.91
HRTX price is $1.91

30-Day Relative Volume

0.54
HRTX 30-day relative volume is 0.54

Price Performance

Price Today change

+4.95%
HRTX price is up +4.95% today

Price YTD change

+24.84%
HRTX price is up +24.84% since January 1st

Price 1-year change

-35.03%
HRTX price is down -35.03% year-on-year

Price 3-year change

-67.24%
HRTX price is down -67.24% over the past 3 years

Price Range

Price All-time high

$1290.00
HRTX price is currently -99.85% below its historical high of $1290.00

Price 3-year low

$0.50
HRTX price is currently +282.00% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$290.95M
HRTX market capitalization is $290.95 million

Market cap 3-year change

-51.14%
HRTX market capitalization is down -51.14% over the past 3 years

Market cap All-time high

$3.18B
HRTX market capitalization is currently -90.85% below its historical high of $3.18 billion

Market cap sector rank

62.61%
HRTX market capitalization is higher than 62.61% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+1.3%
HRTX shares outstanding is up +1.3% year-on-year

Shares Outstanding 3-Year Change

+49.13%
HRTX shares outstanding is up +49.13% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

1.16
HRTX beta is 1.16

200-day SMA

$2.01
HRTX price is currently -4.77% below its 200-day simple moving average

50-day SMA

$2.06
HRTX price is currently -7.17% below its 50-day simple moving average

RSI

41.06
HRTX 14-day relative strength index is 41.06

Volume

0.54
HRTX 30-day relative volume is 0.54

ATR

$0.17
HRTX average true range is $0.17

10-day Historical Volatility

84.31%
HRTX 10-day historical volatility is 84.31%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$144.28M
HRTX annual revenue is $144.28 million

Revenue Analysts estimate

$158.17M
HRTX annual revenue is currently -8.78% lower than the consensus analysts' forecast

Revenue 1-year change

+13.57%
HRTX annual revenue is up +13.57% year-on-year

Revenue Sector rank

60.36%
HRTX annual revenue is higher than 60.36% of companies in Healthcare sector

EPS

EPS

-$0.09
HRTX annual earnings per share is -$0.09

EPS Analysts estimate

-$0.03
HRTX annual earnings per share is currently +200.00% higher than the consensus analysts' forecast

EPS 1-year change

+88.75%
HRTX annual earnings per share is up +88.75% year-on-year

EPS Sector rank

80.51%
HRTX annual earnings per share is higher than 80.51% of companies in Healthcare sector

Profit

Gross profit

$105.64M
HRTX annual gross profit is $105.64 million

Gross margin

73.21%
HRTX annual gross profit margin is 73.21%

Operating profit

-$11.53M
HRTX annual operating income is -$11.53 million

Operating margin

-7.99%
HRTX annual operating profit margin is -7.99%

Net income

-$13.58M
HRTX annual net profit is -$13.58 million

Net margin

-9.41%
HRTX annual net profit margin is -9.41%

Expenses

Total expenses

$155.81M
HRTX annual total expenses is $155.81 million

Operating expenses

$117.17M
HRTX annual total operating expenses is $117.17 million

Cost of goods sold

$38.65M
HRTX annual cost of goods sold is $38.65 million

Selling, general & administrative expenses

$100.48M
HRTX annual SGA is $100.48 million

Depreciation and amortization

$2.49M
HRTX annual depreciation & amortization is $2.49 million

Interest expense

$6.03M
HRTX annual interest expense is $6.03 million

Income tax

-
HRTX annual income tax value is unknown

EBIT & EBITDA

EBIT

-$7.55M
HRTX annual earnings before interest & taxes is -$7.55 million

EBITDA

-$5.06M
HRTX annual EBITDA is -$5.06 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$233.15M
HRTX annual total assets is $233.15 million

Non current assets

$24.13M
HRTX annual long term assets is $24.13 million

Current assets

$209.01M
HRTX annual total current assets is $209.01 million

Cash and cash equivalents

$25.80M
HRTX annual cash & cash equivalents is $25.80 million

Accounts receivable

$78.88M
HRTX annual accounts receivable is $78.88 million

Inventory

$53.16M
HRTX annual inventory is $53.16 million

Liabilities

Total liabilities

$266.80M
HRTX annual total liabilities is $266.80 million

Long term liabilities

$175.34M
HRTX annual total long term liabilities is $175.34 million

Current liabilities

$91.46M
HRTX annual total current liabilities is $91.46 million

Accounts payable

$11.71M
HRTX annual accounts payable is $11.71 million

Debt

Total debt

$177.76M
HRTX annual total debt is $177.76 million

Total debt 1-year change

-1.04%
HRTX annual total debt is down -1.04% year-on-year

Long term debt

$174.73M
HRTX annual long term debt is $174.73 million

Short term debt

$3.04M
HRTX annual short term debt is $3.04 million

Equity & Capital

Shareholders equity

-$33.65M
HRTX annual stockholders equity is -$33.65 million

Book value

-$33.65M
HRTX annual book value is -$33.65 million

Retained earnings

-$1.92B
HRTX annual retained earnings is -$1.92 billion

Working capital

$117.56M
HRTX annual working capital is $117.56 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-$22.53M
HRTX annual cash flow from operations is -$22.53 million

Cash from operations 1-year change

+61.68%
HRTX annual cash flow from operations is up +61.68% year-on-year

Cash from investing

$18.71M
HRTX annual cash flow from investing activities is $18.71 million

Cash from investing 1-year change

+4%
HRTX annual cash flow from investing activities is up +4% year-on-year

Cash from financing

$940.00K
HRTX annual cash flow from financing activities is $940.00 thousand

Cash from financing 1-year change

-98.26%
HRTX annual cash flow from financing activities is down -98.26% year-on-year

CAPEX

CAPEX

$1.71M
HRTX annual capital expenditures is $1.71 million

CAPEX 1-year change

+10.42%
HRTX annual capital expenditures is up +10.42% year-on-year

Free Cash Flow

Free cash flow

-$24.23M
HRTX annual free cash flow is -$24.23 million

Free cash flow 1-year change

+59.83%
HRTX annual free cash flow is up +59.83% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

73.21%
HRTX annual gross profit margin is 73.21%

Operating margin

-7.99%
HRTX annual operating profit margin is -7.99%

Net margin

-9.41%
HRTX annual net profit margin is -9.41%

ROA & ROE

ROA

-5.96%
HRTX annual return on assets is -5.96%

ROE

40.36%
HRTX annual return on equity is 40.36%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
HRTX price to earnings ratio value is unknown

PE ratio Sector rank

-
HRTX price to earnings ratio is unknown

PB Ratio

PB ratio

-8.65
HRTX price to book ratio is -8.65

PB ratio Sector rank

2.71%
HRTX price to book ratio is higher than 2.71% of companies in Healthcare sector

PS Ratio

PS ratio

2.02
HRTX price to sales ratio is 2.02

PS ratio Sector rank

43.59%
HRTX price to sales ratio is higher than 43.59% of companies in Healthcare sector

Enterprise value

Enterprise value

$442.91M
HRTX enterprise value is $442.91 million

Enterprise value Sector rank

68.84%
HRTX enterprise value is higher than 68.84% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-87.60
HRTX EV/EBITDA is -87.60

EV/EBITDA Sector rank

1.39%
HRTX EV/EBITDA is higher than 1.39% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

2.29
HRTX annual current ratio is 2.29

Quick ratio

1.70
HRTX annual quick ratio is 1.70

Leverage

Debt to equity

-5.19
HRTX annual debt to equity ratio is -5.19

Interest coverage ratio

-1.25
HRTX annual interest coverage ratio is -1.25

Risk & Stability

Piotroski F-Score

3
HRTX piotroski f-score is 3

Altman Z-Score

-9.76
HRTX altman z-score is -9.76

Analyst ratings

Recent major analysts updates

Feb 28, 25 Needham
Buy
Dec 4, 24 Needham
Buy
Nov 13, 24 Needham
Buy
Sep 25, 24 Needham
Buy
Aug 7, 24 Needham
Buy
Jun 13, 24 Rodman & Renshaw
Buy
May 16, 24 Needham
Buy
May 8, 24 Needham
Buy
Apr 23, 24 Capital One
Overweight
Apr 11, 24 Needham
Buy

Institutional Ownership

Similar stocks

Oruka Therapeutics (ORKA)
NNOX logo
Nano-X Imaging (NNOX)
BNTC logo
Benitec Biopharma (BNTC)
DH logo
Definitive Healthcare (DH)
RGNX logo
REGENXBIO (RGNX)
VERV logo
Verve Therapeutics (VERV)
HCAT logo
Health Catalyst (HCAT)
RNAC logo
Cartesian Therapeutics (RNAC)
PHAT logo
Phathom Pharmaceuticals (PHAT)
  • What is the ticker symbol for Heron Therapeutics?
  • Does Heron Therapeutics pay dividends?
  • What sector is Heron Therapeutics in?
  • What industry is Heron Therapeutics in?
  • What country is Heron Therapeutics based in?
  • When did Heron Therapeutics go public?
  • Is Heron Therapeutics in the S&P 500?
  • Is Heron Therapeutics in the NASDAQ 100?
  • Is Heron Therapeutics in the Dow Jones?
  • When was Heron Therapeutics's last earnings report?
  • When does Heron Therapeutics report earnings?
  • Should I buy Heron Therapeutics stock now?

What is the ticker symbol for Heron Therapeutics?

The ticker symbol for Heron Therapeutics is NASDAQ:HRTX

Does Heron Therapeutics pay dividends?

No, Heron Therapeutics does not pay dividends

What sector is Heron Therapeutics in?

Heron Therapeutics is in the Healthcare sector

What industry is Heron Therapeutics in?

Heron Therapeutics is in the Biotechnology industry

What country is Heron Therapeutics based in?

Heron Therapeutics is headquartered in United States

When did Heron Therapeutics go public?

Heron Therapeutics's initial public offering (IPO) was on August 26, 1987

Is Heron Therapeutics in the S&P 500?

No, Heron Therapeutics is not included in the S&P 500 index

Is Heron Therapeutics in the NASDAQ 100?

No, Heron Therapeutics is not included in the NASDAQ 100 index

Is Heron Therapeutics in the Dow Jones?

No, Heron Therapeutics is not included in the Dow Jones index

When was Heron Therapeutics's last earnings report?

Heron Therapeutics's most recent earnings report was on Feb 27, 2025

When does Heron Therapeutics report earnings?

The next expected earnings date for Heron Therapeutics is May 7, 2025

Should I buy Heron Therapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page